How do their mechanisms compare
It also inhibits glucagon release and slows gastrointestinal transit, which both reduce appetite
Pathway 2: Chronic weight management (approved November 2023, marketed as Zepbound) You qualify if you have: BMI 30 kg/m or higher (obesity), OR BMI 27 kg/m or higher (overweight) with at least one weight-related comorbid condition The weight management indication uses the brand name Zepbound rather than Mounjaro, but the active ingredient (tirzepatide) and dosing are identical
There is currently no adequate data on whether tirzepatide passes into breast milk, what concentrations might be present, or what effect that exposure could have on a nursing infant
For researchers currently building protocols based on Phase 2 data, the Phase 3 dose selection validates the 4mg to 12mg range as the therapeutic window
However, lower doses like 2.5 mg become harder to measure accurately because you are working with smaller syringe volumes